NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong announce the commencement of an investigation concerning whether Meridian Bioscience, Inc. ("Meridian") (NASDAQ: VIVO) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/VIVO-Info-Request-Form-1610. There is no cost or obligation to you.
On January 25, 2017, Meridian announced disappointing first-quarter 2017 fiscal year financial results, revised its previously-issued revenue guidance for the 2017 fiscal year downwards, and announced that the Board of Directors reduced the annual indicated dividend rate. Chief Executive Officer of Meridian, John A. Kraeutler, attributed the negative first quarter 2017 results to revenue declines in Meridian’s Americas diagnostic business—Meridian’s largest profit driver—across all major product categories, “due to customer buying patterns and general weakness overall.” On this news, shares of Meridian fell over 22% to close at $12.80 per share on January 25, 2017.
To learn more about the investigation of Meridian contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://docs.wongesq.com/VIVO-Info-Request-Form-1610.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.